Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Dominik C. Bader"'
Autor:
Eike Gallmeier, Dominik C Bader, Lydia Kriegl, Sabina Berezowska, Hendrik Seeliger, Burkhard Göke, Thomas Kirchner, Christiane Bruns, Enrico N De Toni
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56760 (2013)
IntroductionAgonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in pri
Externí odkaz:
https://doaj.org/article/e4473de467944c5199b82dfe358e786b
Autor:
Andreas Palagyi, Dominik C. Bader, Thomas Kirchner, Enrico N. De Toni, Eike Gallmeier, Rüdiger P. Laubender, Hendrik Seeliger, Andreas Ziesch, Yang Guo, Stephanie Ochs, Gerald Assmann, Christiane J. Bruns, Denise Buchner, Andreas Jung, Claus Schäfer, Burkhard Göke
Publikováno v:
Journal of Cellular and Molecular Medicine
A role of heat shock protein 27 (HSP27) as a potential biomarker has been reported in various tumour entities, but comprehensive studies in pancreatic cancer are lacking. Applying tissue microarray (TMA) analysis, we correlated HSP27 protein expressi
Autor:
Dominik C. Bader, Michael Haas, Gerald Assmann, Stefan Boeck, Thomas Kirchner, Simone Reu, Eike Gallmeier, Axel Kleespies, Stephan Kruger, Steffen Ormanns, Volker Heinemann
Publikováno v:
Journal of cancer research and clinical oncology. 140(9)
It has not yet been clearly defined whether anaplastic lymphoma kinase (ALK) expression can be detected in pancreatic ductal adenocarcinoma (PDAC). Within a retrospective study, archival PDAC surgical specimens were screened for ALK expression in tum
Autor:
Dominik C. Bader, Enrico N. De Toni, Lydia Kriegl, Sabina Berezowska, Burkhard Göke, Thomas Kirchner, Eike Gallmeier, Hendrik Seeliger, Christiane J. Bruns
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e56760 (2013)
PLoS ONE
Gallmeier, Eike; Bader, Dominik C.; Kriegl, Lydia; Berezowska, Sabina Anna; Seeliger, Hendrik; Göke, Burkhard; Kirchner, Thomas; Bruns, Christiane; De Toni, Enrico N. (2013). Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. PLoS ONE, 8(2), e56760. Public Library of Science 10.1371/journal.pone.0056760
PLoS ONE
Gallmeier, Eike; Bader, Dominik C.; Kriegl, Lydia; Berezowska, Sabina Anna; Seeliger, Hendrik; Göke, Burkhard; Kirchner, Thomas; Bruns, Christiane; De Toni, Enrico N. (2013). Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. PLoS ONE, 8(2), e56760. Public Library of Science 10.1371/journal.pone.0056760
IntroductionAgonistic antibodies targeting TRAIL-receptors 1 and 2 (TRAIL-R1 and TRAIL-R2) are being developed as a novel therapeutic approach in cancer therapy including pancreatic cancer. However, the cellular distribution of these receptors in pri
Autor:
Gerald Assmann, Hendrik Seeliger, Thomas Kirchner, C. J. Bruns, Dominik C. Bader, Eike Gallmeier, Denise Buchner, B. Göke, E N De Toni, Claus Schäfer
Publikováno v:
Journal of Clinical Oncology. 28:e21053-e21053
e21053 Background: Heat shock protein 27 (HSP27) is a stress-inducible protein preventing the accumulation of misfolded proteins and participating in the regulation of apoptosis. The role of HSP27 as a biomarker has been investigated in a variety of